drugset / Trial / NCT04720612
COVID-19 Immunologic Antiviral Therapy With Omalizumab
Phase 2
Unknown
40 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate if omalizumab is effective in decreasing mortality in severe hospitalized COVID-19 cases.
Timeline
- Start
- 2021-10-15
- Primary completion
- 2022-11-07
- Completion
- 2022-12-16
Publications
- Background World Health Organization. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. In. Geneva, Switzerland. 2020.
- Le M, Khoury L, Lu Y, Prosty C, Cormier M, Cheng MP, Fowler R, Murthy S, Tsang JLY, Ben-Shoshan M, Rahme E, Golchi S, Dendukuri N, Lee TC, Netchiporouk E. COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial. Open Forum Infect Dis. 2024 Feb 23;11(4):ofae102. doi: 10.1093/ofid/ofae102. eCollection 2024 Apr.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 375 mg | Subcutaneous |